Gamma Or Immune Patents (Class 424/85.5)
-
Patent number: 8084022Abstract: The present invention relates to alkylglycoside-containing compositions and methods for increasing the stability, reducing the aggregation and immunogenicity, increasing the biological activity, and reducing or preventing fibrillar formation of a peptide, polypeptide, or variant thereof, for example interferons, such as interferon-alpha, interferon-beta, interferon-gamma, and variants thereof.Type: GrantFiled: March 17, 2008Date of Patent: December 27, 2011Assignee: Aegis Therapeutics, LLCInventor: Edward T. Maggio
-
Publication number: 20110311474Abstract: The invention provides compounds of Formula (I) and Formula (II) pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variable are defined herein. The compounds of the invention are useful for treating immunological and oncological conditions.Type: ApplicationFiled: December 1, 2010Publication date: December 22, 2011Applicant: ABBOTT LABORATORIESInventors: Neil WISHART, Maria A. ARGIRIADI, David J. CALDERWOOD, Anna M. ERICSSON, Bryan R. FIAMENGO, Kristine E. FRANK, Michael FRIEDMAN, Dawn M. GEORGE, Eric R. GOEDKEN, Nathan S. JOSEPHSOHN, Biqin C. LI, Michael J. MORYTKO, Kent D. STEWART, Jeffrey W. VOSS, Grier A. WALLACE, Lu WANG, Kevin R. WOLLER
-
Publication number: 20110311481Abstract: Methods and compositions for contributing to the treatment of cancers, especially ovarian tumors, are disclosed. The methods and compositions utilize an endothelin B agonist (ETB) to enhance the delivery and resulting efficacy of chemotherapeutic agent(s) (e.g., cisplatin and/or cyclophosphamide).Type: ApplicationFiled: August 29, 2011Publication date: December 22, 2011Applicants: THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS, SPECTRUM PHARMACEUTICALS, INC.Inventors: Anil Gulati, Guru Reddy, Luigi Lenaz
-
Publication number: 20110305631Abstract: Disclosed herein are compositions and methods of use comprising combinations of anti-CD22 antibodies with a therapeutic agent. The therapeutic agent may be attached to the anti-CD22 antibody or may be separately administered, either before, simultaneously with or after the anti-CD22 antibody. In preferred embodiments, the therapeutic agent is an antibody or fragment thereof that binds to an antigen different from CD22, such as CD19, CD20, CD21, CD22, CD23, CD37, CD40, CD40L, CD52, CD80 and HLA-DR. However, the therapeutic agent may an immunomodulator, a cytokine, a toxin or other therapeutic agent known in the art. More preferably, the anti-CD22 antibody is part of a DNL complex, such as a hexavalent DNL complex. Most preferably, combination therapy with the anti-CD22 antibody or fragment and the therapeutic agent is more effective than the antibody alone, the therapeutic agent alone, or the combination of anti-CD22 antibody and therapeutic agent that are not conjugated to each other.Type: ApplicationFiled: August 19, 2011Publication date: December 15, 2011Applicant: IMMUNOMEDICS, INC.Inventors: Serengulam V. Govindan, David M. Goldenberg
-
Publication number: 20110305667Abstract: The invention relates to the use of a DEAD-box RNA helicase from a yeast, a mammal, Leishmania infantum, or fragments thereof for inducing the production of cytokines by a peripheral blood mononuclear cell (PBMC) of a mammal, and to the applications thereof.Type: ApplicationFiled: June 5, 2009Publication date: December 15, 2011Applicants: INSTITUT PASTEUR DE TUNIS, INSTITUT PASTEURInventors: Ikram Guizani, Mourad Barhoumi, Amel Garnaoui, Nolen Kyle Tanner
-
Publication number: 20110305668Abstract: Particular aspects of the invention provide methods for decreasing the amount of fluid present in the subretinal space of the eye by administering interferon gamma to the basolateral side of the retinal pigment epithelium. Adverse ocular conditions associated with the accumulation of fluid in the subretinal space can be treated by administering an amount of interferon gamma to the basolateral side of the retinal pigment epithelium effective to remove excess fluid from the subretinal space.Type: ApplicationFiled: August 14, 2009Publication date: December 15, 2011Applicant: The United States of America, as represented by the Secretary, Dept.of Health and Human ServicesInventors: Rong Li, Sheldon S. Miller, Arvydas Maminishkis
-
Patent number: 8075916Abstract: A biodegradable and thermosensitive poly(organophosphazene) with a functional group, a preparation method thereof, and a use thereof for delivery of bioactive substances are provided.Type: GrantFiled: May 17, 2008Date of Patent: December 13, 2011Assignee: Korea Institute of Science and TechnologyInventors: Soo-Chang Song, Mi-Ran Park, Sun-Mi Lee
-
Patent number: 8076132Abstract: The invention relates to a method of treating tumor cells within a patient wherein immature dendritic cells developed from the patient's monocyte cells and a lymphocyte cultured medium (LCM) adjuvant are introduced into the patient directly into the patient's tumor cells. The immature dendritic cells and LCM adjuvant combine with the antigens in the tumor cells to form a cancer vaccine, thereby immediately treating the tumor cells of the patient. The invention also provides a precursor treatment step of treating the patient with radiation therapy or a chemotherapy regimen.Type: GrantFiled: April 10, 2008Date of Patent: December 13, 2011Assignee: Hasumi International Research FoundationInventor: Kenichiro Hasumi
-
Publication number: 20110300066Abstract: Disclosed herein are compositions and methods of use comprising combinations of anti-CD74 antibodies with a therapeutic agent. The therapeutic agent may be attached to the anti-CD74 antibody or may be separately administered, either before, simultaneously with or after the anti-CD74 antibody. In preferred embodiments, the therapeutic agent is an antibody or fragment thereof that binds to an antigen different from CD74, such as CD19, CD20, CD21, CD22, CD23, CD37, CD40, CD40L, CD52, CD80, IL-6, CXCR4 and HLA-DR. However, the therapeutic agent may an immunomodulator, a cytokine, a toxin or other therapeutic agent known in the art. More preferably, the anti-CD74 antibody is part of a DNL complex, such as a hexavalent DNL complex. Most preferably, combination therapy with the anti-CD74 antibody or fragment and the therapeutic agent is more effective than the antibody alone, the therapeutic agent alone, or the combination of anti-CD74 antibody and therapeutic agent that are not conjugated to each other.Type: ApplicationFiled: August 15, 2011Publication date: December 8, 2011Applicant: IMMUNOMEDICS, INC.Inventors: Chien-Hsing Chang, David M. Goldenberg, Edmund A. Rossi
-
Publication number: 20110300104Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit RNA-containing virus, particularly the Hepatitis C Virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the Hepatitis C Virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.Type: ApplicationFiled: June 3, 2011Publication date: December 8, 2011Inventors: Yao-Ling Qiu, Ce Wang, Hui Cao, Xiaowen Peng, Datong Tang, Yat Sun Or
-
Publication number: 20110293516Abstract: The present invention concerns compositions comprising and methods of identification and use of targeting peptides for placenta or adipose tissue. In certain embodiments, the targeting peptides comprise part or all of SEQ ID NO:5-11, SEQ ID NO:13-22 or SEQ ID NO:144. The peptides may be attached to various therapeutic agents for targeted delivery. Adipose-targeting peptides may be used in methods for weight control, inducing weight loss and treating lipodystrophy syndrome. Adipose-targeting may also be accomplished using other binding moieties selectively targeted to adipose receptors, such as a prohibitin receptor protein complex. Placenta-targeting peptides may be used to interfere with pregnancy, induce labor and/or for targeted delivery of therapeutic agents to placenta and/or fetus. In other embodiments, receptors identified by binding to placenta-targeting peptides may be used to screen compounds for potential teratogenicity.Type: ApplicationFiled: April 11, 2011Publication date: December 1, 2011Inventors: RENATA PASQUALINI, WADIH ARAP, MIKHAIL G. KOLONIN
-
Patent number: 8066981Abstract: The invention relates to compositions and methods related to Toll-like receptor (TLR) polypeptides. In some embodiments, the invention relates to managing TLR3 related diseases. In further embodiments, the invention relates to methods of preventing and treating inflammation. In some embodiments, the invention relates to antagonists of TLR3, to amino acid sequences that act as dominant negative molecules, and to nucleic acid sequences that encode said amino acid sequences. In additional embodiments, the invention relates to the manipulation of biological materials to evaluate TLR3 activity.Type: GrantFiled: November 14, 2007Date of Patent: November 29, 2011Assignee: The Texas A & M University SystemInventors: Cheng C. Kao, Ranjith Kumar Tharachaparamba
-
Publication number: 20110286967Abstract: A polypeptide and polynucleotides encoding same comprising carboxy-terminal peptides (CTP) of chorionic gonadotrophin attached to an IFN protein are disclosed. Pharmaceutical compositions comprising the polypeptide and polynucleotides of the invention and methods of using same are also disclosed.Type: ApplicationFiled: July 28, 2011Publication date: November 24, 2011Inventors: Fuad Fares, Udi Eyal Fima
-
Publication number: 20110286966Abstract: Modified endogenous human interferon-gamma (hIFN-?), biologically inactive but preserving binding affinity to the hIFN-? receptor, has applicability in the treatment of autoimmune diseases, especially multiple sclerosis.Type: ApplicationFiled: February 28, 2011Publication date: November 24, 2011Inventors: Ivan Ivanov, Rumen Tsanev, Genoveva Nacheva, Hans-Guenther Grigoleit, Rolf Gunther
-
Publication number: 20110286962Abstract: Provided herein are compounds, compositions and methods for the treatment of liver disorder, including HCV and/or HBV infections. Specifically, compound and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents.Type: ApplicationFiled: May 26, 2011Publication date: November 24, 2011Inventors: Jean-Pierre SOMMADOSSI, Gilles Gosselin, Claire Pierra, Christian Perigaud, Suzanne Peyrottes
-
Publication number: 20110280800Abstract: Proteins that bind IL-1? and IL-1? are described along with their use in compositions and methods for treating, preventing, and diagnosing IL-1-related disorders and for detecting IL-1? and IL-1? in cells, tissues, samples, and compositions.Type: ApplicationFiled: May 13, 2011Publication date: November 17, 2011Applicant: ABBOTT LABORATORIESInventors: Chengbin WU, Tariq GHAYUR, Chung-ming HSIEH, Dominic J. AMBROSI
-
Publication number: 20110280829Abstract: Low molecular weight sulphated L-fucose polysaccharide fraction having a molecular weight ranging from 11 to 30 kDa when measured with TEST A, a sulphate content ranging from 10 and 50% w/w relative to the total weight of the fraction, a fucosis content ranging from 30 and 70% w/w relative to the total weight of the fraction, and a polydispersity index ranging from 1 and 2, wherein the fraction is obtainable by free radical depolymerisation of a crude fucan of vegetal origin; process for manufacturing same; pharmaceutical composition and medicament containing same and their use for inhibiting neovascularisation.Type: ApplicationFiled: January 7, 2010Publication date: November 17, 2011Applicant: THERAPOLInventors: Laurent David, Laetitia Frank, Rosa Siali, Jean Huet
-
Publication number: 20110274653Abstract: Immunostimulatory compositions and methods comprising an ITIM motif-containing DC immunoreceptor (DCIR) to mediate potent crosspresentation are described herein. The inventors evaluated human CD8+ T cell responses generated by targeting antigens to dendritic cells (DCs) through various lectin receptors. A single exposure to a low dose of anti-DCIR-antigen conjugate initiated antigen-specific CD8+ T cell immunity by all human DC subsets including ex vivo generated DCs, skin-isolated Langerhans cells and blood mDCs and pDCs. Enhanced specific CD8+ T cell responses were observed when antigens like, FluMP, MART-1, viral (HIV gag), etc. were delivered to the DCs via DCIR, compared to those induced by a free antigen, or antigen conjugated to a control mAb or delivered via DC-SIGN, another lectin receptor. Addition of Toll-like receptor (TLR) 7/8-agonist enhanced DCIR-mediated crosspresentation as well as crosspriming.Type: ApplicationFiled: May 4, 2011Publication date: November 10, 2011Applicant: Baylor Research InstituteInventors: Jacques F. Banchereau, Eynav Klechevsky, Gerard Zurawski, Sandra Zurawski
-
Publication number: 20110274654Abstract: Provided herein are triazole FASN inhibitors of the formula (I): or a pharmaceutically acceptable form thereof; wherein the variables RA, X, RB, and RC are defined herein. Also provided herein are pharmaceutical compositions of the compounds provided herein as well as methods of their use for the treatment of various disorders such as hyperproliferative disorders, inflammatory disorders, obesity-related disorders and microbial infections.Type: ApplicationFiled: May 5, 2011Publication date: November 10, 2011Inventors: Adilah BAHADOOR, Alfredo C. Castro, Lawrence K. Chan, Gregg F. Keaney, Marta Nevalainen, Vesa Nevalainen, Stephane Peluso, Thomas T. Tibbitts
-
Publication number: 20110274656Abstract: The present invention relates to a pharmaceutical composition for preventing or treating Hepatitis C, comprising the roots extract of Platycodon grandiflorum and/or saponin components in Platycodon grandiflorum useful as an antiviral agent. The composition of the present invention has no harm to human and inhibits the proliferation of Hepatitis C virus, so that it can be effectively used as a preventive or therapeutic agent for Hepatitis C.Type: ApplicationFiled: January 21, 2010Publication date: November 10, 2011Applicant: B&C Biopharm Co., Ltd.Inventors: Jong Woo Kim, Sang Wook Lee, Sang Jin Park, Jung Cheul Shin, Jae Won Yang, Jong Hwan Lim
-
Publication number: 20110274655Abstract: Provided herein are tetrazolone FASN inhibitors of the formula (I): or a pharmaceutically acceptable form thereof; wherein the variables RA, RB and RC are defined herein. Also provided herein are pharmaceutical compositions of the compounds provided herein as well as methods of their use for the treatment of various disorders such as hyperproliferative disorders, inflammatory disorders, obesity-related disorders and microbial infections.Type: ApplicationFiled: May 5, 2011Publication date: November 10, 2011Applicant: Infinity PharmaceuticalsInventors: Adilah BAHADOOR, Alfredo C. Castro, Lawrence K. Chan, Gregg F. Keaney, Marta Nevalainen, Vesa Nevalainen, Stephane Peluso, Daniel A. Snyder, Thomas T. Tibbitts
-
Patent number: 8048862Abstract: The embodiments provide compounds of the general Formulae I, II, III, IV, V, VI, VII, and X, as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments further provide treatment methods, including methods of treating a hepatitis C virus infection and methods of treating liver fibrosis, the methods generally involving administering to an individual in need thereof an effective amount of a subject compound or composition.Type: GrantFiled: April 14, 2009Date of Patent: November 1, 2011Assignee: InterMune, Inc.Inventors: Scott D. Seiwert, Leonid Beigelman, Brad Buckman, Antitsa Dimitrova Stoycheva, Steven B. Porter, Williamson Ziegler Bradford, Vladimir Serebryany
-
Publication number: 20110262398Abstract: Disclosed herein are reagents and methods for detecting and treating age-related diastolic dysfunction in an animal or a human.Type: ApplicationFiled: April 21, 2011Publication date: October 27, 2011Applicant: UNIVERSITY OF ILLINOISInventors: Samuel C. Dudley, Roy L. Sutliff
-
Publication number: 20110250172Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.Type: ApplicationFiled: April 8, 2011Publication date: October 13, 2011Inventors: Yao-Ling Qiu, Ce Wang, Xiaowen Peng, Yat Sun Or
-
Publication number: 20110250171Abstract: The invention relates to immunotherapeutic compounds and to methods for stimulating an immune response in a subject individual at risk for developing cancer, diagnosed with a cancer, in treatment for cancer, or in post-therapy recovery from cancer or the compounds of the invention can be administered as a prophylactic to a subject individual to prevent or delay the development of cancer.Type: ApplicationFiled: June 13, 2011Publication date: October 13, 2011Applicant: Eisai R&D Management Co., Ltd.Inventors: Daniel P. Rossignol, Sally T. Ishizaka, Lynn D. Hawkins, Scott Z. Fields
-
Publication number: 20110250173Abstract: The present invention relates to methods of suppressing the immune tolerance of a disease or disease antigens in a patient. The method also promotes the activity of the effector T lymphocytes. The invention includes administering a therapeutic composition that promotes a Th1 environment in the patient while decreasing the immunosuppressive activity of Treg cells that can lead to disease antigen tolerance and immunoavoidance of the disease antigens by the patient. The therapeutic composition includes allogeneic emTh-1 cells. The therapeutic composition can also include disease antigens such as the chaperone-rich cell lysate of the disease antigen.Type: ApplicationFiled: April 12, 2011Publication date: October 13, 2011Applicant: Immunovative Therapies Ltd.Inventor: Michael Har-Noy
-
Publication number: 20110250174Abstract: The invention relates to a stable immunogenic product for the induction of antibodies against one or more antigenic proteins in a subject. The invention is characterised in that it comprises proteinaceous immunogenic heterocomplexes which are formed by associations between (i) antigenic protein molecules and (ii) proteinaceous carrier molecules and in that less than 40% of the antigenic proteins (i) are linked to the proteinaceous carrier molecules (ii) by a covalent bond.Type: ApplicationFiled: May 31, 2011Publication date: October 13, 2011Applicant: NEOVACSInventors: Helene LE BUANNEC, Daniel ZAGURY
-
Publication number: 20110243841Abstract: Disclosed herein are methods and compositions comprising anti-CD74 and/or anti-HLA-DR antibodies for treatment of GVHD and other immune dysfunction diseases. In preferred embodiments, the anti-CD74 and/or anti-HLA-DR antibodies are effective to deplete antigen-presenting cells, such as dendritic cells. Most preferably, administration of the therapeutic compositions depletes all subsets of APCs, including mDCs, pDCs, B cells and monocytes, without significant depletion of T cells. In alternative embodiments, administration of the therapeutic compositions suppresses proliferation of allo-reactive T cells, while preserving cytomegalovirus (CMV)-specific, CD8+ memory T cells. The compositions and methods provide a novel conditioning regimen for preventing aGVHD and/or treating chronic GVHD, without altering preexisting anti-viral immunity.Type: ApplicationFiled: March 29, 2011Publication date: October 6, 2011Applicant: IMMUNOMEDICS, INC.Inventors: Chien-Hsing Chang, David M. Goldenberg
-
Publication number: 20110243891Abstract: The present invention relates to a compound of General Formula (I) below, among others. In the Formula, Ar1 is an optionally substituted aryl or heteroaryl group; R1 is a hydrogen atom, an optionally substituted C1-C6 alkyl group, or an optionally substituted aryl, aralkyl, or heteroaryl group; R2 is an optionally substituted aryl, aralkyl, or heteroaryl group; and R3 is a hydrogen atom or a C1-C6 alkyl group. A compound of the present invention has an excellent Weel kinase inhibiting effect, and is therefore useful in the filed of medicine, particularly in various types of cancer therapy.Type: ApplicationFiled: December 9, 2009Publication date: October 6, 2011Inventors: Makoto Bamba, Hidetomo Furuyama, Toshihiro Sakamoto, Satoshi Sunami, Keiji Takahashi, Fuyuki Yamamoto, Takashi Yoshizumi
-
Publication number: 20110243892Abstract: The present invention relates to Y-shape branched PEG derivatives of formulae (I) to (IV). The present invention also relates to conjugates of these Y-shape derivatives and drug molecules, pharmaceutical compositions comprising those conjugates.Type: ApplicationFiled: June 17, 2011Publication date: October 6, 2011Inventors: Shishan Ji, Dequan Zhu
-
Publication number: 20110236304Abstract: The present invention provides substituted humanized, chimeric or human anti-CD20 antibodies or antigen binding fragments thereof and bispecific antibodies or fusion proteins comprising the substituted antibodies or antigen binding fragments thereof. The antibodies, fusion proteins or fragments are useful for treatment of B-cell disorders, such as B-cell malignancies and autoimmune diseases, as well as GVHD, organ transplant rejection, and hemolytic anemia and cryoglobulinemia. Amino acid substitutions, particularly substitution of an aspartate residue at Kabat position 101 of CDR3 VH (CDRH3), result in improved therapeutic properties, such as decreased dissociation rates, improved CDC activity, improved apoptosis, improved B-cell depletion and improved therapeutic efficacy at very low dosages.Type: ApplicationFiled: March 1, 2011Publication date: September 29, 2011Applicant: IMMUNOMEDICS, INC.Inventors: David M. GOLDENBERG, Chien-Hsing CHANG, Hans J. HANSEN
-
Publication number: 20110236349Abstract: The present invention provides methods of treating a viral infection in an individual. The methods generally involve administering to an individual an effective amount of an epidermal growth factor receptor (EGF-R) inhibitor.Type: ApplicationFiled: December 16, 2009Publication date: September 29, 2011Inventors: Jonathan L. Koff, Jay A. Nadel
-
Publication number: 20110229407Abstract: The present invention provides humanized, chimeric and human anti-alpha-fetoprotein antibodies, fusion proteins, and fragments thereof. The antibodies, fusion proteins, and fragments thereof, as well as combinations with other suitable antibodies, are useful for the treatment and diagnosis of hepatocellular carcinoma, hepatoblastoma, germ cell tumors carcinoma and other AFP-producing tumors.Type: ApplicationFiled: April 20, 2011Publication date: September 22, 2011Applicant: IMMUNOMEDICS, INC.Inventors: Hans J. Hansen, Zhengxing Qu, David M. Goldenberg
-
Publication number: 20110223133Abstract: An inducing agent or enhancing agent, for the expression of HM1.24 antigen in hematopoietic tumor cells, comprising interferon ?, interferon ?, or the IRF-2 protein as an active ingredient, as well as an antitumor agent for hematopoietic tumors which comprises a combination of said inducing agent or enhancing agent and an antibody against HM1.24.Type: ApplicationFiled: April 13, 2011Publication date: September 15, 2011Applicant: Chugai Seiyaku Kabushiki KaishaInventors: Masaaki KOSAKA, Shuji Ozaki, Yuji Wakahara
-
Publication number: 20110223230Abstract: A polymeric prodrug composition including a hydrogel, a biologically active moiety and a reversible prodrug linker. The prodrug linker covalently links the hydrogel and the biologically active moiety at a position and the hydrogel has a plurality of pores with openings on its surface. The diameter of the pores is larger than that of the biologically active moiety at least at all points of the pore between at least one of the openings and the position of the biologically active moiety.Type: ApplicationFiled: May 19, 2011Publication date: September 15, 2011Applicant: ASCENDIS PHARMA A/SInventors: Ulrich Hersel, Harald Rau, Robert Schnepf, Dirk Vetter, Thomas Wegge
-
Patent number: 8012475Abstract: Method of treating autoimmune conditions are disclosed comprising administering to a mammalian subject IL-12 or an IL-12 antagonist. In certain preferred embodiments the autoimmune condition is one which is promoted by an increase in levels of IFN-? or TNF-?. Suitable conditions for treatment include multiple sclerosis, systemic lupus erythematosus, rheumatoid arthritis, autoimmune pulmonary inflammation, Guillain-Barre syndrome, autoimmune thyroiditis, insulin dependent diabetes melitis and autoimmune inflammatory eye disease.Type: GrantFiled: May 14, 2009Date of Patent: September 6, 2011Assignee: Genetics Institute, LLCInventors: John Leonard, Samuel Goldman, Richard O'Hara, Jr.
-
Publication number: 20110212168Abstract: The present disclosure relates to a composition for targeting dendritic cells. In particular, the present disclosure relates to a composition comprising: a) one or more antigens; b) an anti-DC-SIGN immunoglobulin single variable domain; and c) a carrier which carries a) and b). The disclosure further relates to formulations, compositions and devices comprising such anti-DC-SIGN molecules and their use as a medicament and in the treatment of cancer, suitably melanoma.Type: ApplicationFiled: October 19, 2009Publication date: September 1, 2011Inventors: Joseph Altin, Ines Atmosukarto, Rudolf Maria De Wildt, Christopher Parish, Jason Price
-
Publication number: 20110212055Abstract: Methods and compositions for treating neuropathies.Type: ApplicationFiled: March 25, 2009Publication date: September 1, 2011Inventor: John W. Commissiong
-
Patent number: 8007774Abstract: The present invention relates to biodegradable scaffolds composed of a naturally-occurring protein backbone cross-linked by a synthetic polymer. Specifically, the present invention provides PEGylated-fibrinogen scaffold and methods of generating and using same for treating disorders requiring tissue regeneration.Type: GrantFiled: June 22, 2006Date of Patent: August 30, 2011Assignee: Regentis Biomaterials Ltd.Inventors: Dror Seliktar, Liora Almany
-
Publication number: 20110208168Abstract: A liquid composition in an osmotic drug delivery system and a dosage form in an osmotic drug delivery system is disclosed comprising an amphiphilic molecule, a non-aqueous liquid solvent, and a pharmaceutically active agent.Type: ApplicationFiled: April 21, 2011Publication date: August 25, 2011Inventors: Rom Ezer Eliaz, Yuanpeng Zhang, Catherine Manya Rohloff, Eric William Weeks, Gunjan Junnarkar
-
Publication number: 20110195110Abstract: Pyrazole urea compounds, pharmaceutical compositions which contain them and methods for treating cancer using them.Type: ApplicationFiled: December 1, 2006Publication date: August 11, 2011Inventors: Roger Smith, Holia N. Hatoum-Mokdad, Louis David Cantin, Donald E. Bierer, Wenlang Fu, Dhanapalan Nagarathnam, Gaetan Ladouceur, Yamin Wang, Herbert Ogutu, Scot Wilhelm, Ian Taylor, Sanjeeva Reddy, Richard Gedrich, Christopher Carter, Aaron Schmitt, Xiaomei Zhang
-
Publication number: 20110195020Abstract: The present invention concerns methods and compositions for making and using bioactive assemblies of defined compositions, which may have multiple functionalities and/or binding specificities. In particular embodiments, the bioactive assembly is formed using dock-and-lock (DNL) methodology, which takes advantage of the specific binding interaction between dimerization and docking domains (DDD) and anchoring domains (AD) to form the assembly. In various embodiments, one or more effectors may be attached to a DDD or AD sequence. Complementary AD or DDD sequences may be attached to an adaptor module that forms the core of the bioactive assembly, allowing formation of the assembly through the specific DDD/AD binding interactions. Such assemblies may be attached to a wide variety of effector moieties for treatment, detection and/or diagnosis of a disease, pathogen infection or other medical or veterinary condition.Type: ApplicationFiled: February 4, 2011Publication date: August 11, 2011Applicant: IBC PHARMACEUTICALS, INC.Inventors: Chien-Hsing Chang, David M. Goldenberg, William J. McBride, Edmund A. Rossi
-
Publication number: 20110189085Abstract: The present invention provides a composition comprising naked humanized, chimeric, and human anti-CEA antibodies and a therapeutic agent, which is useful for treatment of CEA expressing cancers and other diseases, and methods of use in treatment using this composition.Type: ApplicationFiled: February 18, 2011Publication date: August 4, 2011Applicant: IMMUNOMEDICS, INC.Inventors: David M. Goldenberg, Hans J. Hansen
-
Publication number: 20110189129Abstract: The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, esters, or prodrugs thereof: Q-G-A-L-B—W??(I), which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.Type: ApplicationFiled: January 25, 2011Publication date: August 4, 2011Inventors: Yao-Ling Qiu, Ce Wang, Xiaowen Peng, Lu Ying, Hui Cao, Yat Sun Or
-
Publication number: 20110189130Abstract: The invention relates to compounds of a general formula (I): wherein Ar1 is an optionally-substituted aryl or heteroaromatic group; R1 is an optionally-substituted lower alkyl, lower alkenyl, lower alkynyl or cyclo-lower alkyl group, or is an aryl, aralkyl or heteroaromatic group optionally having a substituent; R2 is a hydrogen atom, a lower alkyl group, a lower alkenyl group or a lower alkynyl group, or is an aryl, aralkyl or heteroaromatic group optionally having a substituent; R3 is a hydrogen atom or a lower alkyl group; R4 is a hydrogen atom, a halogen atom, a hydroxyl group, a lower alkyl group or a group of —N(R1k)R1m; T and U are a nitrogen atom or a methine group, etc. The compounds of the invention have excellent Weel kinase-inhibitory effect and are therefore useful in the field of medicines, especially treatment of various cancers.Type: ApplicationFiled: March 22, 2011Publication date: August 4, 2011Inventors: Takeshi Sagara, Sachie Otsuki, Satoshi Sunami, Toshihiro Sakamoto, Kenji Niiyama, Fuyuki Yamamoto, Takashi Yoshizumi, Hidetomo Furuyama, Yasuhiro Goto, Makoto Bamba, Keiji Takahashi, Hiroshi Hirai, Toshihide Nishibata
-
Publication number: 20110189083Abstract: The present invention concerns methods and compositions for forming anti-cancer vaccine DNL complexes using dock-and-lock technology. In preferred embodiments, the anti-cancer vaccine DNL complex comprises an antibody moiety that binds to dendritic cells, such as an anti-CD74 antibody or antigen-binding fragment thereof, attached to an AD (anchoring domain) moiety and a xenoantigen, such as CD20, attached to a DDD (dimerization and docking domain) moiety, wherein two copies of the DDD moiety form a dimer that binds to the AD moiety, resulting in the formation of the DNL complex. The anti-cancer vaccine DNL complex is capable of inducing an immune response against xenoantigen expressing cancer cells, such as CD138negCD20+ MM stem cells, and inducing apoptosis of and inhibiting the growth of or eliminating the cancer cells.Type: ApplicationFiled: January 21, 2011Publication date: August 4, 2011Applicant: IBC PHARMACEUTICALS, INC.Inventors: Chien-Hsing Chang, David M. Goldenberg
-
Publication number: 20110182857Abstract: Liquid pharmaceutical compositions for administration to a mucosal surface, including a therapeutic agent and a pectin with a low degree of esterification are described. Such compositions gel, or can be adapted to gel, at the site of application in the absence of an extraneous source of divalent metal ions.Type: ApplicationFiled: April 1, 2011Publication date: July 28, 2011Applicant: ARCHIMEDES DEVELOPMENT LIMITEDInventors: Peter James WATTS, Lisbeth ILLUM
-
Publication number: 20110182856Abstract: The present invention relates to compounds of formula (I): or a pharmaceutically acceptable salt thereof. These compounds inhibit serine protease, particularly the hepatitis C virus NS3-NS4A protease.Type: ApplicationFiled: March 29, 2011Publication date: July 28, 2011Applicant: Vertex Pharmaceuticals IncorporatedInventors: Kevin M. Cottrell, John Maxwell, Qing Tang, Anne-Laure Grillot, Amaud Le Tiran, Emanuele Perola
-
Publication number: 20110177026Abstract: The present invention provides methods for treating a flavivirus infection, including hepatitis C virus (HCV) infection, in an individual suffering from a flavivirus infection. In some embodiments, the methods involve administering to an individual in need thereof an effective amount of an agent that inhibits enzymatic activity of a membrane-bound ?-glucosidase inhibitor. In other embodiments, the methods involve administering to an individual in need thereof effective amounts of an ?-glucosidase inhibitor and at least one additional therapeutic agent.Type: ApplicationFiled: February 10, 2011Publication date: July 21, 2011Applicant: INTERMUNE, INC.Inventors: Lawrence M. Blatt, Hua Tan, Scott D. Seiwert
-
Publication number: 20110177027Abstract: The invention relates to a combination therapy for the treatment of tumors metastases comprising administration of anti-angiogenic agents and tumor necrosis factor alpha (TNFa) optionally together with other cytotoxic agents, such as interferon gamma (IFNy) or chemotherapeutic agents such as anti-EGFR antibodies. The method and the pharmaceutical compositions comprising said agents can result in a synergistic potentiation of the tumor cell proliferation inhibition effect of each individual therapeutic agent, yielding more effective treatment than found by administering an individual component alone.Type: ApplicationFiled: March 21, 2011Publication date: July 21, 2011Inventors: Matthias GRELL, Simon GOODMAN, Curzio RUEGG